Sugi Predict

Sugi Predict / Compounds / SCHEMBL23926510

SCHEMBL23926510

SCHEMBL23926510

CN(C)C(=O)c1cc2cc([N+](=O)[O-])cnc2n1C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.46
▸ AURKA O14965 3/20 0.46
▸ MAPT P10636 4/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ LMNA P02545 2/20 0.36
▸ KMT2A Q03164 3/20 0.35
▸ HTT P42858 1/20 0.35
▸ CYP2C19 P33261 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CCNA2 P20248 2/20 0.34
▸ TTK P33981 2/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ KAT2B Q92831 1/20 0.32
▸ CDK4 P11802 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28656405 0.84 KMT2A (0.40) MAPTALDH1A1LMNAKMT2AHTT
SCHEMBL23926525 0.83 ALDH1A1 (0.39) MAPTALDH1A1LMNAKMT2AHTT
SCHEMBL23926520 0.82 CDK2 (0.48) CDK2AURKACCNA2TTKCDK4
SCHEMBL31349390 0.80 GAA (0.41) MAPTALDH1A1LMNA
SCHEMBL18181365 0.76 CDK2 (0.47) CDK2AURKAPOLBCCNA2TTK
SCHEMBL22130122 0.74 MAPT (0.42) MAPTALDH1A1LMNACYP2C19POLB
SCHEMBL23926516 0.73 CDK2 (0.42) CDK2AURKAMAPTALDH1A1LMNA
SCHEMBL23926464 0.70 NOD1 (0.42) MAPTALDH1A1LMNAKMT2AL3MBTL1
SCHEMBL13092243 0.69 GABRG2 (0.35) CDK2AURKAKMT2ATTKMEN1
SCHEMBL23926505 0.69 MAPT (0.44) MAPTALDH1A1LMNAKMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 — — US disclosed
CN-113727972-B Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof 韩国科学技术研究院 2024-12-27 — — CN disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 — — US disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 CDK2 4016/4885AURKA 2230/4885MAPT 3633/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT CDK2 2511/4885AURKA 226/4885MAPT 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.